Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601281 | 0.84 | NR1H2 (0.51) | CYP3A4SMN1; SMN2KDM4EHPGDLMNA | |
| SCHEMBL10150591 | 0.83 | SMN1; SMN2 (0.39) | CYP3A4SMN1; SMN2HPGDALDH1A1TDP1 | |
| SCHEMBL429496 | 0.81 | CYP3A4 (0.56) | CYP3A4SMN1; SMN2KDM4EHPGDLMNA | |
| SCHEMBL15695711 | 0.80 | CYP3A4 (0.50) | CYP3A4SMN1; SMN2KDM4EHPGDLMNA | |
| SCHEMBL6587703 | 0.79 | ALDH1A1 (0.44) | CYP3A4SMN1; SMN2KDM4EHPGDLMNA | |
| SCHEMBL7601139 | 0.79 | CYP3A4 (0.42) | CYP3A4SMN1; SMN2KDM4EHPGDLMNA | |
| SCHEMBL571273 | 0.79 | CYP3A4 (0.61) | CYP3A4SMN1; SMN2KDM4EHPGDALDH1A1 | |
| SCHEMBL11570737 | 0.78 | SMN1; SMN2 (0.39) | CYP3A4SMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL11570734 | 0.78 | SMN1; SMN2 (0.39) | CYP3A4SMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL7631407 | 0.78 | CYP3A4 (0.59) | CYP3A4SMN1; SMN2KDM4EHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100558724-C | Adjust active sulphonamide of endothelium peptide and derivative thereof | ANSEHIV PHARMACEUTICAL CORP (US) | 2009-11-11 | — | — | CN | disclosed |
| CN-1215069-C | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-08-17 | — | — | CN | disclosed |
| CN-1530366-A | Sulphonic acid amide for regulating bast peptide activity and derivative thereof | ��ɪϣ����ҩ��˾ | 2004-09-22 | — | — | CN | disclosed |
| EP-0946552-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | disclosed |
| US-6632829-B2 | Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases | TEXAS BIOTECHNOLOGY CORP. | 2003-10-14 | — | — | US | disclosed |
| EP-1342721-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6420567-B1 | PRODRUGS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-07-16 | — | — | US | disclosed |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
| CN-1231664-A | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 1999-10-13 | — | — | CN | disclosed |
| EP-0946552-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998013366-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | CYP3A4 1652/4885SMN1; SMN2 2313/4885KDM4E 2082/4885 |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | CYP3A4 1652/4885SMN1; SMN2 2313/4885KDM4E 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.